Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Hexarelin vs CJC-1295 + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Hexarelin has stronger documented evidence (Phase 2 (not approved)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Hexarelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Hexarelin

Phase 2 (not approved)

CJC-1295 + Ipamorelin

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Hexarelin CJC-1295 + Ipamorelin
Class GHRP; potent ghrelin receptor agonist GHRH analog + selective GHRP blend (GH-secretagogue stack)
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHS-R1a agonist; more potent GH release than other GHRPs Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm).
Route SC / Intranasal SC injection
Half-life ~1 hr CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs
Dosage (research) 100-200 mcg SC 1-2x daily (short cycles) 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off
Evidence tier Phase 2 (not approved) Anecdotal + Animal Studies
Research depth 158 indexed (PubMed 141 · CT 0 · EPMC 17) 5 indexed (PubMed 0 · CT 0 · EPMC 5)
Availability Research Chemical Compounding Restricted
Reported risks Cortisol/prolactin elevation; pituitary desensitization Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Hexarelin or CJC-1295 + Ipamorelin?

Hexarelin has stronger documented evidence (Phase 2 (not approved)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Hexarelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Hexarelin and CJC-1295 + Ipamorelin?

Hexarelin is classed as GHRP; potent ghrelin receptor agonist; CJC-1295 + Ipamorelin is classed as GHRH analog + selective GHRP blend (GH-secretagogue stack). Reported mechanism: Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs; CJC-1295 + Ipamorelin, Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). Reported half-life: Hexarelin, ~1 hr; CJC-1295 + Ipamorelin, CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs. Routes in published studies: Hexarelin, SC / Intranasal; CJC-1295 + Ipamorelin, SC injection.

Which has stronger evidence, Hexarelin or CJC-1295 + Ipamorelin?

Hexarelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies. CJC-1295 + Ipamorelin is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 5 indexed studies.

Which is more accessible, Hexarelin or CJC-1295 + Ipamorelin?

Neither Hexarelin nor CJC-1295 + Ipamorelin is an FDA-approved drug. Catalog status: Hexarelin, Research Chemical; CJC-1295 + Ipamorelin, Compounding Restricted.

Are Hexarelin and CJC-1295 + Ipamorelin ever combined?

Hexarelin and CJC-1295 + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…